1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  available in person


6. For how long will this data be available start date provided 17-03-2024 and end date provided 17-03-2028?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - nil

General anaesthesia was one of the most common methods employed to provide anaesthesia for upper limb surgeries. With the introduction of newer and safer local anaesthetics and better advantages, regional anaesthesia has taken over as the principal technique for upper limb surgeries.

Regional anaesthesia is comparatively safer and does not involve the potential side effects and complications that may arise from sedation and general anaesthesia. It is also effective as it more acceptable amongst the patients, thus providing the doctors an increased patient compliance and consent for surgery. The infraclavicular block is a safe and effective approach for Brachial plexus block that can provide anaesthesia for hands, wrist and forearm.

Ropivacaine is a propyl analogue of bupivacaine that has the same potency with longer duration of action and lesser cardiac and central nervous system toxicity of bupivacaine. Several adjuvants can be used to lengthen the duration of infraclavicular brachial plexus block such as clonidine, opioids, neostigmine, midazolam and buprenorphine ^[1].

Clonidine, a selective alpha-2 adrenergic agonist inhibits nociceptive impulses by activating postjunctional alpha-2 adrenoreceptors both at peripheral and spinal nerve endings. It improves block characteristics of local anaesthetics in peripheral nerve blocks without producing any side effects like sedation, bradycardia and hypotension as seen in spinal blocks ^[2].

Buprenorphine is a dehydroxylated phenanthrene and is chemically similar to other opioids such as hydrocodone, oxycodone, levorphanol, hydromorphone, oxymorphone, and others. Buprenorphine is a partial agonist at the m-opioid receptor (MOR) and an antagonist at k receptors. As a partial agonist, buprenorphine is able to activate MORs at low to moderate doses and it can achieve the same or superior analgesia compared to a full m-opioid agonist ^[3].

There are studies that compare the effects of adding clonidine as an adjuvant to ropivacaine or bupivacaine for brachial plexus blocks ^[1]. But there are limited studies with buprenorphine as an adjuvant in infraclavicular blocks.

After thorough research in literature, it was concluded that limited data is available that compares and assess the effects of these drugs as adjuvants to ropivacaine.

Hence, this study is being undertaken which intends to compare and evaluate the effects of clonidine and buprenorphine as adjuvants to ropivacaine in infraclavicular brachial plexus blocks.